Gilead Sciences, Inc. $GILD Shares Purchased by OFI Invest Asset Management

OFI Invest Asset Management lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 124.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 849,277 shares of the biopharmaceutical company’s stock after acquiring an additional 470,804 shares during the period. Gilead Sciences accounts for approximately 1.3% of OFI Invest Asset Management’s investment portfolio, making the stock its 14th biggest holding. OFI Invest Asset Management’s holdings in Gilead Sciences were worth $104,240,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. SOA Wealth Advisors LLC. grew its holdings in Gilead Sciences by 8.7% during the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 81 shares in the last quarter. Trivium Point Advisory LLC grew its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. Binnacle Investments Inc grew its holdings in Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 83 shares in the last quarter. Hemington Wealth Management grew its holdings in Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 85 shares in the last quarter. Finally, Ignite Planners LLC grew its holdings in Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Tubulis for up to $5.0B (≈$3.15B upfront + up to $1.85B in milestones), adding an ADC platform and clinical assets (TUB‑040, TUB‑030) to bolster its oncology pipeline — a clear strategic push to diversify into higher-growth cancer therapies. Gilead to Acquire Tubulis (BusinessWire)
• Positive Sentiment: Several sell‑side analysts reiterated or kept bullish views after the M&A wave: Needham and Bernstein expressed constructive views (Needham kept a Buy with a $170 target), signaling investor interest in the deal’s long‑term upside to Gilead’s oncology franchise. Needham: Buy on Tubulis (TipRanks)
• Positive Sentiment: Underlying fundamentals remain solid: Gilead has a recent history of earnings beats and set FY‑2026 EPS guidance (8.45–8.85), which supports valuation while the company reinvests in growth areas. (Earnings/guidance referenced from recent filings and reports.)
• Neutral Sentiment: RBC raised its price target (from $118 to $123) but kept a “sector perform” rating — the new target still sits below current levels, reflecting cautious upside in the bank’s view despite the strategic rationale. RBC adjusts price target on Gilead (MarketScreener)
• Neutral Sentiment: Market headlines note the stock has risen but still slightly underperformed broader indexes over the short term — momentum is positive but not yet broad‑based. Gilead stock rises but underperforms (MarketWatch)
• Negative Sentiment: Some analysts caution on execution and integration risk from a flurry of acquisitions — Goldman Sachs kept a Hold, citing execution risk and the potential for near‑term distraction or cost pressure as Gilead assimilates multiple deals. Goldman Sachs Hold on Gilead (TipRanks)
• Negative Sentiment: The $5B deal includes sizable contingent payments and upfront cash outlays; investors focused on near‑term cash flow, margin impact, or dilution from additional M&A may view the transaction as a risk until assets advance clinically. Gilead to acquire Tubulis (Reuters)

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the sale, the insider owned 131,779 shares in the company, valued at approximately $19,006,485.17. This trade represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the sale, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. The trade was a 1.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 299,280 shares of company stock worth $42,820,550 over the last ninety days. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

GILD has been the subject of a number of recent analyst reports. Rothschild & Co Redburn raised their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Daiwa Securities Group raised their price objective on shares of Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a report on Friday, March 6th. Finally, The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $157.81.

Gilead Sciences Trading Up 2.0%

Shares of NASDAQ:GILD opened at $141.54 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The company has a market cap of $175.68 billion, a PE ratio of 20.91, a P/E/G ratio of 1.83 and a beta of 0.39. The company’s 50-day moving average price is $145.13 and its 200 day moving average price is $130.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the business earned $1.90 earnings per share. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio (DPR) is 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.